Laboratory Stock News

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomark...

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FD...

BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025.

Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that...

Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive gen...

Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like t...

Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - De...

Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.